Filtered By:
Condition: Ischemic Stroke
Countries: USA Health
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 575 results found since Jan 2013.
CO142 Evaluating the Impact of the COVID-19 Pandemic on Acute Ischemic Stroke Outcomes in the Stroke Belt
This study sought to compare specific key outcomes related to ischemic stroke that occurred before and during the COVID-19 pandemic. We assessed mortality rates, morbidity rates, and the administration of thrombolytics in patients with ischemic stroke admitted to emergency departments (ED) in the Stroke Belt, a region of the United States with historically worse stroke outcomes.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: E. Stitzlein, F. Pathan, I. Weimer, K. Lodaya, F. D'Souza, A. Shenoy Source Type: research
Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Media News - May 17, 2023 Category: Pharmaceuticals Source Type: news
EMAGINE –Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke
Stroke is a leading cause of disability with limited effective interventions that improve recovery in the subacute phase. This protocol aims to evaluate the safety and efficacy of a non-invasive, extremely low-frequency, low-intensity, frequency-tuned electromagnetic field treatment [Electromagnetic Network Targeting Field (ENTF) therapy] in reducing disability and promoting recovery in people with subacute ischemic stroke (IS) with moderate-severe disability and upper extremity (UE) motor impairment. Following a sample-size adaptive design with a single interim analysis, at least 150 and up to 344 participants will be rec...
Source: Frontiers in Neurology - May 5, 2023 Category: Neurology Source Type: research
Intra-arterial thrombolysis as adjunct to mechanical thrombectomy in acute ischemic stroke patients in the United States: A case control analysis
Although observational studies have reported favorable clinical outcomes associated with intra-arterial thrombolysis as adjunct to mechanical thrombectomy, the cost and length of hospitalization associated with this intervention has not been studied.
Source: Journal of Stroke and Cerebrovascular Diseases - May 5, 2023 Category: Neurology Authors: Chun Shing Kwok, Navpreet K. Bains, Daniel E. Ford, Camilo R. Gomez, Daniel F. Hanley, Ameer E. Hassan, Thanh N. Nguyen, Farhan Siddiq, Alejandro M. Spiotta, Syed F. Zaidi, Adnan I. Qureshi Source Type: research
The Impact of Full Collapse on the Risk of Ischaemic Stroke in Patients with Carotid Near Occlusion
Carotid near occlusion (CNO) is a severe carotid stenosis associated with a reduction in the calibre of the extracranial internal carotid artery distal to the stenosis.1 The risk of ipsilateral stroke in patients with CNO is a controversial issue. While a post hoc analysis of the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) reported a lower risk of ipsilateral stroke for medically treated patients with CNO compared with patients with severe (70 –99%) carotid stenosis2, more recent studies have shown that the CNO recurrence rate may be higher.
Source: European Journal of Vascular and Endovascular Surgery - April 20, 2023 Category: Surgery Authors: Andr és García-Pastor, Ana Iglesias-Mohedano, Antonio Gil-Núñez Tags: Editorial Source Type: research
Mechanisms of in-hospital acute ischemic stroke and their relevance to prognosis: A retrospective analysis
In-hospital stroke (IHS) refers to stroke that occurs during hospitalization in patients admitted for other diagnoses,1 of which ischemic stroke is the most common type, accounting for approximately 60% to 89%.2,3 IHS is common with approximately 35,000 to 75,000 patients having a stroke while hospitalized in the United States each year.4 The incidence of IHS tends to increase per year,5 resulting in a serious social burden. In-hospital ischemic strokes are widely distributed across various in-hospital departments.
Source: Journal of Stroke and Cerebrovascular Diseases - April 11, 2023 Category: Neurology Authors: Juanjuan Wu, Guangsong Han, Yuhui Sha, Mingyu Tang, Ziang Pan, Ziyue Liu, Yicheng Zhu, Lixin Zhou, Jun Ni Source Type: research
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines
AbstractPurpose of ReviewStroke is a leading cause of death and disability worldwide. The annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the United States, of which 87% are ischemic in nature. In addition to the management of modifiable high-risk factors to reduce the risk of recurrent stroke, antithrombotic agents (antiplatelets and anticoagulants) play an important role in secondary stroke prevention. This review will discuss the published literature on the use of antiplatelets and anticoagulants in secondary prevention of acute ischemic stroke and transient ischemic attack (TIA), ...
Source: Current Neurology and Neuroscience Reports - April 11, 2023 Category: Neuroscience Source Type: research
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Vagus Nerve Stimulation Paired with Upper-Limb Rehabilitation After Stroke: Two- and Three-Year Follow-up from the Pilot Study
CONCLUSIONS: Significant effects of Paired VNS therapy at one year were maintained at years 2 and 3, and further improvements in both impairment and function were observed in years 2 and 3. These changes were associated with improvements in measures of activity and participation.PMID:37001842 | DOI:10.1016/j.apmr.2023.02.012
Source: Health Physics - March 31, 2023 Category: Physics Authors: Gerard E Francisco Navzer Engineer Jesse Dawson Teresa J Kimberley Steven Cramer Cec ília N Prudente David Pierce Brent W Tarver Reema H Adham Hinds Ann Van de Winckel Nuray Yozbatiran Source Type: research
Exploring the bi-directional relationship and shared genes between depression and stroke via NHANES and bioinformatic analysis
Conclusion: We successfully identified the ten hub shared genes linking the IS and MDD and constructed the regulatory networks for them that could serve as novel targeted therapy for the comorbidities.
Source: Frontiers in Genetics - March 31, 2023 Category: Genetics & Stem Cells Source Type: research
Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis
CNS Neurol Disord Drug Targets. 2023 Mar 9. doi: 10.2174/1871527322666230309100626. Online ahead of print.ABSTRACTStroke is a multifactorial vascular disease and remains a leading cause of disability in the United States. Strokes can be ischemic or hemorrhagic in nature and secondary to arterial or venous disease, making determining the etiology and secondary prevention strategy important for preservation of the injured brain, prevention of recurrent strokes, and in the maintenance of good functional outcomes for patients impacted by stroke. In this narrative review, we provide a synopsis of the available medical evidence ...
Source: CNS and Neurological Disorders Drug Targets - March 9, 2023 Category: Drugs & Pharmacology Authors: Dylan Ryan Tarun Girotra Wuwei Feng Source Type: research
